PPIDT00378

Drug Information
NameSemaglutide
SequenceNot Available
DrugBank_IDDB13928
Typesmall molecule
IndicationSemaglutide is always intended to be used with a reduced calorie diet and increased physical activity. It is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus.[L8678,L8681] However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not intended for use in patients with type 1 diabetes or to treat diabetic ketoacidosis.[L8678] Semaglutide is indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol).[L34475,L41335]. Semaglutide it is also indicated for chronic weight management in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex.[L44552] Semaglutide is also used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.[L50452]
Dosage Forms
Form Route Strength
Injection, solution Parenteral; Subcutaneous
0.25 MG
Injection, solution Parenteral; Subcutaneous
0.5 MG
Injection, solution Parenteral; Subcutaneous
1 MG
Injection, solution Parenteral; Subcutaneous
1.34 MG/ML
Injection, solution Parenteral; Subcutaneous
2 mg
Injection, solution Subcutaneous
0.25 mg/0.19ml
Injection, solution Subcutaneous
0.5 mg/0.37ml
Injection, solution Subcutaneous
0.68 mg/1mL
Injection, solution Subcutaneous
1 mg/0.74ml
Injection, solution Subcutaneous
1.34 mg/1mL
Injection, solution Subcutaneous
2 mg/0.74ml
Injection, solution Subcutaneous
2.68 mg/1mL
Solution Subcutaneous
0.68 mg / mL
Solution Subcutaneous
1.34 mg / mL
Solution Subcutaneous
1.340 mg
Solution Subcutaneous
2.68 mg / mL
Injection, solution Subcutaneous
1.34 mg/ml
Solution Subcutaneous
134000 mg
Tablet Oral
1.5 mg
Tablet Oral
1.5 mg/1
Tablet Oral
14 mg/1
Tablet Oral
14 mg
Tablet Oral
25 mg
Tablet Oral
3 mg
Tablet Oral
3 mg/1
Tablet Oral
3.0 mg
Tablet Oral
4 mg
Tablet Oral
4 mg/1
Tablet Oral
50 mg
Tablet Oral
7 mg
Tablet Oral
7 mg/1
Tablet Oral
9 mg
Tablet Oral
9 mg/1
Tablet Oral
1400000 mg
Tablet Oral
300000 mg
Tablet Oral
700000 mg
Injection, solution Subcutaneous
0.25 mg
Injection, solution Subcutaneous
0.25 mg/0.5mL
Injection, solution Subcutaneous
0.5 mg
Injection, solution Subcutaneous
0.5 mg/0.5mL
Injection, solution Subcutaneous
1 mg
Injection, solution Subcutaneous
1.0 mg/0.5mL
Injection, solution Subcutaneous
1.7 mg/0.75mL
Injection, solution Subcutaneous
1.7 mg
Injection, solution Subcutaneous
2.4 mg
Injection, solution Subcutaneous
2.4 mg/0.75mL
Solution Subcutaneous
0.25 mg / 0.5 mL
Solution Subcutaneous
0.5 mg / 0.5 mL
Solution Subcutaneous
0.68 mg
Solution Subcutaneous
1 mg / 1.5 mL
Solution Subcutaneous
1 mg / 0.5 mL
Solution Subcutaneous
1.7 mg / 0.75 mL
Solution Subcutaneous
2 mg / 3 mL
Solution Subcutaneous
2 mg / 1.5 mL
Solution Subcutaneous
2.4 mg / 0.75 mL
Solution Subcutaneous
4 mg / 3 mL
Solution Subcutaneous
6.8 mg / 3 mL
Solution Subcutaneous
9.6 mg / 3 mL
Injection, solution —
0.25 mg
Injection, solution —
0.5 mg
Injection, solution —
1 mg
Injection, solution —
1.7 mg
Injection, solution —
2.4 mg
Solution Subcutaneous
0.25 mg
Solution Subcutaneous
227000 mg
Solution Subcutaneous
320000 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P43220 GLP1R Glucagon-like peptide 1 receptor Homo sapiens agonist Link
enzyme P27487 DPP4 Dipeptidyl peptidase 4 Homo sapiens substrate Link
enzyme P08473 MME Neprilysin Homo sapiens substrate Link
enzyme P06858 LPL Lipoprotein lipase Homo sapiens inhibitor Link
carrier P02768 ALB Albumin Homo sapiens substrate Link